1.O'Brien, KL et al. (2009) Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. The Lancet 374, 893–902.
2.Drijkoningen, JJC and Rohde, GGU (2014) Pneumococcal infection in adults: burden of disease. Clinical Microbiology and Infection 20(suppl. 5), 45–51.
3.Department of Health (2018) Pneumococcal. Immunisation Against Infectious Disease. The Green Book. London: Department of Health.
4.Houseman, C et al. (2017) Increased invasive pneumococcal disease, North East England, UK. Emerging Infectious Diseases 23, 122–126.
5.Ladhani, SN et al. (2018) Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infectious Diseases 18, 441–451.
6.Flasche, S et al. (2011) Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Medicine 8, e1001017.
7.van Hoek, AJ et al. (2014) Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine 32, 4349–4355.
8.Marrie, TJ et al. (2018) Invasive pneumococcal disease in Northern Alberta, not a Red Queen but a dark horse. Vaccine 36, 2985–2990.
9.Oligbu, G et al. (2017) Childhood deaths attributable to invasive pneumococcal disease in England and Wales, 2006–2014. Clinical Infectious Diseases 65, 308–314.
10.Becker-Dreps, S et al. (2017) Changes in the incidence of pneumonia, bacterial meningitis, and infant mortality 5 years following introduction of the 13-valent pneumococcal conjugate vaccine in a ‘3+0’ schedule. PLoS ONE 12, e0183348.
11.Backhaus, E et al. (2016) Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors. BMC Infectious Diseases 16, 367.
12.Grau, I et al. (2016) Declining mortality from adult pneumococcal infections linked to children's vaccination. Journal of Infection 72, 439–449.
13.Harboe, ZB et al. (2014) Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clinical Infectious Diseases 59, 1066–1073.
14.van Hoek, AJ et al. (2012) Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PLoS ONE 7, e39150.
15.Chapman, KE, Wilson, D and Gorton, R (2013) Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England. Epidemiology and Infection 141, 344–352.
16.Hosmer, DW and Lemeshow, S (2001) Applied Logistic Regression, 2nd edn. New York: John Wiley & Sons, Inc.
17.Sauerbrei, W et al. (2006) Multivariable regression model building by using fractional polynomials: description of SAS, STATA and R programs. Computational Statistics & Data Analysis 50, 3464–3485.
18.Hughes, GJ et al. (2016) Serotype-specific differences in short- and longer-term mortality following invasive pneumococcal disease. Epidemiology and Infection 144, 2654–2669.
19.Weinberger, DM et al. (2010) Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clinical Infectious Diseases 51, 692–699.
20.Grabenstein, JD and Musey, LK (2014) Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults. Vaccine 32, 2399–2405.
21.Navarro-Torné, A et al. (2015) Risk factors for death from invasive pneumococcal disease, Europe, 2010. Emerging Infectious Disease 21, 417–425.
22.Harboe, ZB et al. (2009) Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Medicine 6, e10000081.
23.Cruickshank, HC, Jefferies, JM and Clarke, SC (2014) Lifestyle risk factors for invasive pneumococcal disease: a systematic review. BMJ Open 4, e005224.